Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scor...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Jincong Q., Shubeck, Sarah, Howard, Frederick M., Chen, Nan, Nanda, Rita, Huo, Dezheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164191/
https://www.ncbi.nlm.nih.gov/pubmed/37149628
http://dx.doi.org/10.1038/s41523-023-00536-z
_version_ 1785038019480256512
author Freeman, Jincong Q.
Shubeck, Sarah
Howard, Frederick M.
Chen, Nan
Nanda, Rita
Huo, Dezheng
author_facet Freeman, Jincong Q.
Shubeck, Sarah
Howard, Frederick M.
Chen, Nan
Nanda, Rita
Huo, Dezheng
author_sort Freeman, Jincong Q.
collection PubMed
description OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients.
format Online
Article
Text
id pubmed-10164191
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101641912023-05-08 Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients Freeman, Jincong Q. Shubeck, Sarah Howard, Frederick M. Chen, Nan Nanda, Rita Huo, Dezheng NPJ Breast Cancer Brief Communication OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients. Nature Publishing Group UK 2023-05-06 /pmc/articles/PMC10164191/ /pubmed/37149628 http://dx.doi.org/10.1038/s41523-023-00536-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Freeman, Jincong Q.
Shubeck, Sarah
Howard, Frederick M.
Chen, Nan
Nanda, Rita
Huo, Dezheng
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title_full Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title_fullStr Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title_full_unstemmed Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title_short Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
title_sort evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164191/
https://www.ncbi.nlm.nih.gov/pubmed/37149628
http://dx.doi.org/10.1038/s41523-023-00536-z
work_keys_str_mv AT freemanjincongq evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients
AT shubecksarah evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients
AT howardfrederickm evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients
AT chennan evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients
AT nandarita evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients
AT huodezheng evaluationofmultigeneassaysaspredictorsforresponsetoneoadjuvantchemotherapyinearlystagebreastcancerpatients

Ejemplares similares